Vasi Pharma

Vasi Pharma Transforming how new medicines are discovered through deep science.

02/03/2026

Chemistry
Transform materials and processes through precise molecular design for breakthroughs in medicine, technology, and sustainability.

02/03/2026

Alzheimer’s disease remains a vast, urgent problem—about 7.2 million Americans age 65+ are living with Alzheimer’s dementia in 2025, and once diagnosed, people typically survive ~4–8 years (some longer), reflecting a progressive loss of independence and high caregiver burden. Recently approved anti-amyloid antibodies have moved the field forward but leave substantial unmet need: lecanemab slowed clinical decline by 27% on CDR-SB at 18 months in early AD, and donanemab earned FDA approval after a Phase 3 trial showing significantly slowed cognitive and functional decline (reported as ~35% in sponsor disclosures). 60xx is our investigational small-molecule program aimed at complementing these modalities by addressing upstream drivers of neurodegeneration (e.g., synaptic loss and neuroinflammatory pathways). We’re optimizing 60xx for high CNS-relevant potency and drug-like properties with a biomarker-guided strategy to enable rational combinations and patient selection—ultimately aiming to translate into slower decline and longer, higher-quality survival than today’s options. (60xx is investigational and not approved.)

Address

150 N Research Campus Dr
Kannapolis, NC
28081

Website

Alerts

Be the first to know and let us send you an email when Vasi Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category